Pre-Conference Workshop Day: Monday 29 April 2025

Workshop A: Managing Equipment Lead Times Effectively to Mitigate Delays & Keep Projects on Schedule

9 AM - 12 PM

Join this session to deepen your understanding of GLP-1’s multifaceted role in 
metabolic regulation. Gain insights into the intricate intracellular signaling pathways activated by GLP-1, unravel the gut-brain axis and its influence on appetite, and explore the unique advantages of GLP-1 combination therapies. Elucidating the intracellular signaling pathways activated by GLP-1 stimulation

  • Uncovering the gut-brain axis and exploring the neural pathways involved in GLP-1 mediated appetite regulation and satiety
  • Delving into GLP-1 vs GIP mechanisms: what makes this the ideal combination?
  • Exploring and identifying drug combinations that target different aspects of metabolic dysfunction and work towards complementary mechanisms of action
  • Understanding the basic mechanism of amylin analogs that increases efficacy of GLP-1
  • Diving into the synergistic effects of drug combinations to amplify the therapeutics benefits of GLP-1 agonists such as DPP-4 and SGLT2 inhibitors
  • Improving the tolerability of combination therapies from a mechanistic viewpoint
  • Discussing the limitations of genetic resistance to GLP-1s and discussing the options to improve outcomes for GLP-1 resistance patients
  • Future directions: Exploring the potential of novel GLP-1 analogs with enhances potency and selectivity

Workshop Leaders

Andrew Young

Andrew Young
Chief Scientific Medical Officer
I2o Therapeutics

 

 

Marco Falasca

Marco Falasca
Professor
University of Parma

 

 

Workshop B: Mechanistic Insights and Translational Implications of Biased Signalling at the GLP-1 Receptor: Assessing the Therapeutic Potential of Biased Agonists

1 PM - 4 PM

Join this workshop for a comprehensive overview of how receptor conformational
changes drive ligand-specific signaling, with a focus on biased agonism. Delve into the preclinical, translational and clinical findings, exploring the potential for personalized medicine approaches based on patient-specific signaling profiles and discuss the development of biomarkers to predict treatment response.

  • Assessing the role of receptor conformational changes in ligand-specific activation of signaling pathways
  • Utilization of advanced techniques to elucidate structural determinants of biased signalling.
  • Future considerations in designing and interpreting preclinical studies to assess the therapeutic potential of biased agonists to influence the next wave of GLP-1 therapeutics
  • Translation of preclinical findings to clinical trials and evaluation of clinical efficacy and safety.
  • Diving into the potential for tailoring GLP-1 therapies to patients based on their characteristics and signalling profiles for increased specificity
  • Developing biomarkers to accurately predict response to biased agonists
  • Using biased signalling insights to develop GLP-1 therapies with improved efficacy, safety, and tolerability
  • Exploring novel therapeutic applications for GLP-1 receptor agonists using biased
    signalling pathways

Workshop Leader

Jacek Mokrosinski

Jacek Mokrosinski
Senior Scientist
Novo Nordisk

EVENT GUIDE
REGISTER
PARTNER